CliffBio
small molecule

KRINTAFEL

TAFENOQUINE SUCCINATE

Loss of exclusivity—loss of exclusivity
CompanyGLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND

Drug detail

Brand nameKRINTAFEL
Active ingredientTAFENOQUINE SUCCINATE
StrengthEQ 150MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2018
Marketing statusRX

More from GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

KRINTAFEL patent cliff — loss of exclusivity — | CliffBio